CellREADY® drug product IV dose of 100 millions

Preclinical

CellREADY® drug product IV dose of 100 millions is one of 52 therapeutic programs targeting Alzheimer disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Alzheimer DiseaseRecruiting

Alzheimer DiseasePreclinical

Recruiting

Competition

Competitive Landscape

171 competitors in Alzheimer Disease

#DrugCompanyPhaseTrials

Kisunla

Eli Lilly

Phase 3

2 2

Tirazone

Karxt

3 4

Karx-EC

Bristol-Myers Squibb

Phase 3

2 5

Aquasol E

NNational Eye Institute (NEI)

Aricept

2 7

Naproxen Sodium

Exelon

1 9

Namenda

AbbVie

Phase 2

1 10

Leukine

Sanofi

Phase 2

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

PreclinicalRecruiting

Alzheimer Disease

NCT07367815

Clinical

Trials by Indication[1]

Alzheimer disease1 trial

Allogeneic Intraveinous Injection of Adipose Tissue Derived-mesenchymal Stem Cells in Mild to Moderate Alzheimer Disease: a Phase I/II Trial

Recruiting·UUniversity Hospital, Toulouse·Preclinical·NCT07367815·9 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CellREADY® drug product IV dose of 100 millions. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for CellREADY® drug product IV dose of 100 millions. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — University Hospital, Toulouse company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: UUniversity Hospital, Toulouse

CellREADY® drug product IV dose of 100 millions

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Alzheimer disease1 trial

References

Drug Info

Quick Facts

Related News